NKTX Share Price | Nkarta, Inc. Stock Analysis & Recommendation

Q: What does Nkarta, Inc. do?

Overview: Nkarta, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Net Profit: -32 Million (Quarterly Results - Mar 2025) Market Cap: USD 128.43 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.69 Return on Equity: -29.37% Price to Book: 0.34Contact Details: Address: 6000 Shoreline Court, Suite 102, SOUTH SAN FRANCISCO CA: 94080 Tel: 1 650 2150385 Website: https://www.nkartatx.com/

Q: Who are in the management team of Nkarta, Inc.?

As of March 2022, the management team of Nkarta, Inc. includes the following individuals:- Dr. Ali Behbahani, who serves as the Independent Chairman of the Board and Director.- Mr. Paul Hastings, who is the President, Chief Executive Officer, and Director.- Dr. Tiba Aynechi, who is an Independent Director.- Mr. Fouad Azzam, who is also an Independent Director.- Dr. Michael Dybbs, serving as an Independent Director.- Dr. Simeon George, who is an Independent Director.- Ms. Leone Patterson, who is an Independent Director.In summary, the management team consists of a mix of independent directors and key executive leadership.

Q: Is Nkarta, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Nkarta, Inc. has changed from mildly bearish to mildly bullish. The MACD indicates a mildly bullish stance on both weekly and monthly time frames. The daily moving averages also reflect a mildly bullish position. However, the Bollinger Bands show a mixed signal with a bullish weekly outlook and a bearish monthly perspective. The KST is bullish weekly but bearish monthly, while the Dow Theory presents a mildly bearish weekly view contrasted by a mildly bullish monthly outlook. The OBV is mildly bearish weekly and mildly bullish monthly.Despite the current mildly bullish technical stance, Nkarta has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -20.08% versus the S&P 500's 12.22%, and a one-year return of -62.24% compared to 17.14% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

445.6 k

Shareholding (Sep 2025)

FII

10.14%

Held by 42 FIIs

DII

53.81%

Held by 26 DIIs

Promoter

19.35%

How big is Nkarta, Inc.?

22-Jun-2025

As of Jun 18, Nkarta, Inc. has a market capitalization of 128.43 million and reported net sales of 0.00 million with a net profit of -111.24 million for the latest four quarters. As of Dec 24, the company has shareholder's funds of 407.98 million and total assets of 501.20 million.

View full answer

What does Nkarta, Inc. do?

22-Jun-2025

Nkarta, Inc. is a biopharmaceutical company specializing in allogeneic, off-the-shelf engineered natural killer cell therapies for cancer treatment. It has a market cap of approximately $128.43 million and reported a net profit loss of $32 million as of March 2025.

View full answer

Who are in the management team of Nkarta, Inc.?

22-Jun-2025

As of March 2022, Nkarta, Inc.'s management team includes Dr. Ali Behbahani (Independent Chairman), Mr. Paul Hastings (CEO), and several independent directors: Dr. Tiba Aynechi, Mr. Fouad Azzam, Dr. Michael Dybbs, Dr. Simeon George, and Ms. Leone Patterson. The team features a blend of executive leadership and independent oversight.

View full answer

Is Nkarta, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Nkarta, Inc. shows a mildly bullish technical trend, though it has significantly underperformed the S&P 500 with a year-to-date return of -20.08% compared to the index's 12.22%.

View full answer

Compare Nkarta, Inc. with Similar Stocks

HCW Biologics Inc.Syros Pharmaceuticals, Inc.Elicio Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 162 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.82

Return on Equity

-30.37%

Price to Book

0.48

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-22 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

21.11%

6 Months

6.86%

1 Year

45.33%

2 Years

-75.56%

3 Years

-35.31%

4 Years

-80.83%

5 Years

-94.16%

Nkarta, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-197.76%

EBIT to Interest (avg)

-108.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.69

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.48

EV to EBIT

0.93

EV to EBITDA

1.01

EV to Capital Employed

-1.84

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-30.37%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 39 Schemes (16.65%)

Foreign Institutions

Held by 42 Foreign Institutions (10.14%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 23.32% vs -10.55% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-25.00",
          "val2": "-31.40",
          "chgp": "20.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.70",
          "val2": "-28.30",
          "chgp": "23.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.40% vs -3.25% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-119.00",
          "val2": "-125.80",
          "chgp": "5.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-108.80",
          "val2": "-117.50",
          "chgp": "7.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-25.00

-31.40

20.38%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-21.70

-28.30

23.32%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 23.32% vs -10.55% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-119.00

-125.80

5.41%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-108.80

-117.50

7.40%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.40% vs -3.25% in Dec 2023

All Annual Results

Company CV

About Nkarta, Inc.

Nkarta, Inc.

Pharmaceuticals & Biotechnology

Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This platform is modular, which enables optimization of different ways to enhance the natural signaling of engineered cells, as well as the ability to attach and optimize new targeting receptors. The Company’s lead product candidates are NKX101 and NKX019. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells and understanding of NK cell biology.

Company Coordinates

Company Details

6000 Shoreline Court, Suite 102 , SOUTH SAN FRANCISCO CA : 94080

Tel: 1 650 2150385

https://www.nkartatx.com/

Registrar Details